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INTRODUCTION 
This book contains the submitted abstracts for the oral and poster free Communications accepted for 
presentation at the 13th Congress of the International Diabetes Federation. The abstracts have been 
reproduced in the form in which they were submitted. 
Abstracts for plenary lectures and symposia are not included. The manuscripts of these presentations 
will be published in the Proceedings of the Congress which may be ordered at the Elsevier desk at the 
Congress. 
The book is arranged with the oral free Communications at the front followed by the poster free 
Communications. The abstracts are arranged and indexed according to the Session in which they are 
presented. For example, ORA-015-003 refers to the third presentation in session of 15 of the oral free 
Communications and POS-003-172 refers to poster 172 in the third poster session. The poster 
presentation number also represents the poster board number, ie POS-003-172 will appear on poster 
board No. 172. For convenience, a preliminary programme is included in this book. The final 
Programme, which may contain some minor alterations, is included in the programme booklet in your 
satchel. 
Programme and Publications Committees 
13th IDF Congress 




Epidemiology of diabetes 
(ORA-001-001 - ORA-001-008) S3 
Diabetic nephropathy 
(ORA-002-001 - ORA-002-008) S7 
Insulin: Gene expression/Synthesis /Secret ion 
(ORA-003-001 - ORA-003-008) S i l 
Diet and oral agents in diabetes therapy 
(ORA-004-001 - ORA-004-008) S15 
Practical aspects of health care delivery in diabetes 
(ORA-005-001 - ORA-005-008) S19 
Insulin therapy 
(ORA-006-001 - ORA-006-008) S23 
Entero-pancreatic hormones 
(ORA-007-001 - ORA-007-008) S27 
Basic mechanisms of diabetic complications 
(ORA-008-001 - ORA-008-008) S31 
Lipids, atherosclerosis and diabetes 
(ORA-009-001 - ORA-009-008) S35 
Insulin receptors and mechanisms of insulin action - I 
(ORA-010-001 - ORA-010-008) S39 
Diabetes education 
(ORA-011-001 - ORA-011-008) S43 
Immuno therapy and pancreatic transplantation 
(ORA-012-001 - ORA-012-008) S47 
Pathogenesis of Type I diabetes 
(ORA-013-001 - ORA-013-008) S51 
Diabet ic neuropathy 
(ORA-014-001 - ORA-014-008) S55 
Insulin receptors and mechanisms of insulin action - II 
(ORA-015-001 - ORA-015-008) S59 
Growth h o r m o n e / I G F 
(ORA-016-001 - ORA-016-008) S63 
Diabetic retinopathy 
(ORA-017-001 - ORA-017-008) S67 
Glucose metabolism in vitro and in vivo 
(ORA-018-001 - ORA-018-008) S71 
Poster Sessions 
G u t hormones and diabetes 
(POS-001-001 - POS-001-006) S77 
Glucagon and somatostatin 
(POS-001-007 - POS-001-024) S80 
Catecholamines 
(POS-001-025 - POS-001-033) S89 
Growth h o r m o n e s / I G F 
(POS-001-034 - POS-001-051) S94 
Insulin synthesis and gene expression 
(POS-001-052 - POS-001-057) S103 
Insulin secretion I 
(POS-001-058 - POS-001-075) S106 
Metabolism I: In vivo 
(POS-001-076 - POS-001-102) S115 
Pathogenesis of Type I diabetes I 
(POS-001-103 - POS-001-130) S129 
Diabetic complications I 
(POS-001-131 - POS-001-151) S143 
Lipids I 
(POS-001-152 - POS-001-166) S154 
Insulin therapy I 
(POS-001-167 - POS-001-191) S162 
Immunotherapy 
(POS-001-192 - POS-001-209) S175 
Genetics of diabetes 
(POS-001-210 - POS-001-232) S184 
Atherosclerosis in diabetes - Basic mechanisms 
(POS-001-233 - POS-001-245) S196 
Epidemiology I 
(POS-001-246 - POS-001-264) S203 
Health care I 
(POS-001-265 - POS-001-283) S213 
Insulin secretion II 
(POS-002-001 - POS-002-013) S223 
Insulin receptors /Mechanisms of insulin action I 
(POS-002-014 - POS-002-037A) S230 
Metabolism II: In vitro 
(POS-002-038 - POS-002-047) S243 
Pathogenesis of Type I diabetes II 
(POS-002-048 - POS-002-076) S248 
Aetiology of Type II diabetes 
(POS-002-077 - POS-002-097) S263 
Quantitative approaches to metabolism 
(POS-002-098 - POS-002-105) S274 
Diabetic complications II 
(POS-002-106 - POS-002-128A) S278 
Diabetic compl ica t ions /Re t inopa thy I 
(POS-002-129 - POS-002-146) S290 
Diabetic nephropathy I 
(POS-002-147 - POS-002-164A) S299 
Neuropathy I 
(POS-002-165 - POS-002-182) S309 
Diet and oral therapy I 
(POS-002-183 - POS-002-200) S318 
Pancreas transplantat ion 
(POS-002-201 - POS-002-221) S327 
Epidemiology II 
(POS-002-222 - POS-002-241) S338 
Health care II 
(POS-002-242 - POS-002-258) S348 
Insulin secretion in vivo I 
(POS-003-001 - POS-003-017) S357 
Insulin receptors /Mechanisms of insuhn action II 
(POS-003-018 - POS-003-041) S366 
Animal models of diabetes I 
(POS-003-042 - POS-003-061) S378 
Nutrit ion and obesity 
(POS-003-062 - POS-003-084) S388 Ketogenesis and ketoacidosis 85 90 400
Glycosylation 
(POS-003-091 - POS-003-114) S403 
Diabetic compl ica t ions /Basic mechanisms I 
(POS-003-115 - POS-003-136) S415 
Diabetic nephropathy II 
(POS-003-137 - POS-003-154) S426 
Neuropathy II 
(POS-003-155 - POS-003-174) S435 
Lipids II 
(POS-003-175 - POS-003-190) S445 
Pregnancy and diabetes 
(POS-003-191 - POS-003-219) S453 
Insuün therapy II 
(POS-003-220 - POS-003-240) S468 
Diet and oral therapy II 
(POS-003-241 - POS-003-260) S479 
Epidemiology III 
(POS-003-261 - POS-003-278) S489 
Diabetes education I 
(POS-003-279 - POS-003-294) S498 
Insulin secretion in vivo II 
(POS-004-001 - POS-004-012) S506 
Insuün receptors /Mechanisms of insulin action III 
(POS-004-013 - POS-004-026) S512 
Neural control 
(POS-004-027 - POS-004-039) S519 
Animal models of diabetes II 
(POS-004-040 - POS-004-055) S526 
Exercise 
(POS-004-056 - POS-004-066) S534 
Diabetes control 
(POS-004-067 - POS-004-086) S540 
Diabetic complicat ions/Basic mechanisms II 
(POS-004-087 - POS-004-106) S550 
Diabetic compl ica t ions /Ret inopathy II 
(POS-004-107 - POS-004-121) S560 
Diabetic nephropathy III 
(POS-004-122 - POS-004-137) S568 
Neuropathy III 
(POS-004-138 - POS-004-156) S576 
Atherosclerosis, hypertension and diabetes 
(POS-004-157 - POS-004-184) S586 
Insulin therapy III 
(POS-004-185 - POS-004-207) S600 
Diet and oral therapy III 
(POS-004-208 - POS-004-226) S612 
Clinical hypoglycaemia 
(POS-004-227 - POS-004-244) S622 
Epidemiology IV 
(POS-004-245 - POS-004-263) S631 
Diabetes education II 
(POS-004-264 - POS-004-277) S641 
Psychological and behavioral aspects of diabetes 
(POS-004-278 - POS-004-293) S648 
Author index S657 
POS-002-024 
ISOPROTERENOL DECREASES ACTIVATION BY INSULIN OF INSULIN RECEPTOR KINASE 
IN INTACT RAT ADIPOCYTES. 
H.H. KLEIN1, S. MATTHAEI2, P.C. SCRIBA1 
Departments of Internal Medicine^University of Lübeck and 2University of Hamburg, FRG. 
It has been previously shown that ß-adrenergic agonists produce insulin(I)-resistance 
both in vivo and in vitro. We have studied the effect of isoproterenol(ISO) on I-binding 
and activation of insulin receptor kinase(IRK) in intact rat adipocytes. Cell concentra-
tion was <2xl03/ml in buffer containing 2%BSA and 40mM Hepes (pH 7.4). Preincubation with 
ISO (ltyiM) was for 30min at 37<>C. l 2 s I - I was then added to a fraction of the cells for 
15min at 37°C to measure I-binding. The other cells were exposed to various concentra-
tions of I for 15min at 37°C in order to activate the cellular IRK. IRK was then isolated 
and immunoprecipitated in the presence of Phosphatase inhibitors. Under these conditions, 
IRK-activity that resulted from exposure to insulin while the cells were intact, was pre-
served. It was subsequently measured in the presence of 0.5 /iM 32P-ATP and lmg/ml histone 
and was (fmol P into histone/pmol I-binding activity/min): 
Insulin(ng/ml): 0 4 20 500 
-ISO : 4.6+1.0 30.5+5.1 93.8+11.6 124.8+39.3 
+ISO : 4.3+1.1 22.8+2.5 66.1+ 1.0 112.0+27.8 
Mean values for trace I-binding to the cells were: -ISO:0,49+0.12; +180:0,45+0.08%. 
Conclusions: (1)Exposure of the cells to insulin stimulated IRK-activity 25-30fold. 
(2) Activation of IRK by I in intact cells was reduced up to 30% in the presence of ISO. 
(3) Only a minimal, i f any, reduction of I-binding to the cells was observed in the pre-
sence of ISO. (4)0ur data thus suggest that ISO reduces I-activation of IRK in intact 
cells on a post-binding level. 
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